BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 21617238)

  • 21. Improved outcomes in the management of esophageal cancer with the addition of surgical resection to chemoradiation therapy.
    McKenzie S; Mailey B; Artinyan A; Metchikian M; Shibata S; Kernstine K; Kim J
    Ann Surg Oncol; 2011 Feb; 18(2):551-8. PubMed ID: 20839062
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Multimodality treatment in the management of esophageal cancer: neoadjuvant chemoradiotherapy followed by transhiatal esophagectomy.
    Irwin JF; Waterfield W; Poussin-Rosillo H; Sardi A
    Md Med J; 1997 Oct; 46(9):471-76. PubMed ID: 9327648
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Split-course concomitant radiochemotherapy plus surgery vs. surgery alone in squamous cell carcinoma of the esophagus. A non-randomized retrospective study of 184 patients].
    Malhaire JP; Lozac'h P; Simon H; Labat JP; Topart P; Lucas B; Metges JP; Lamezec B
    Bull Cancer; 1997 Apr; 84(4):357-67. PubMed ID: 9238158
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Death-associated protein kinase (DAPK) promoter methylation and response to neoadjuvant radiochemotherapy in esophageal cancer.
    Brabender J; Arbab D; Huan X; Vallböhmer D; Grimminger P; Ling F; Neiss S; Bollschweiler E; Schneider PM; Hölscher AH; Metzger R
    Ann Surg Oncol; 2009 May; 16(5):1378-83. PubMed ID: 19224282
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pretreatment gene expression profiles can be used to predict response to neoadjuvant chemoradiotherapy in esophageal cancer.
    Duong C; Greenawalt DM; Kowalczyk A; Ciavarella ML; Raskutti G; Murray WK; Phillips WA; Thomas RJ
    Ann Surg Oncol; 2007 Dec; 14(12):3602-9. PubMed ID: 17896157
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Who profits from neoadjuvant radiochemotherapy for locally advanced esophageal carcinoma?
    Elsaleh H; Farrell JJ; Crane CH
    J Gastroenterol Hepatol; 2009 May; 24(5):708-10. PubMed ID: 19646012
    [No Abstract]   [Full Text] [Related]  

  • 27. Downregulation of TS, DPD, ERCC1, GST-Pi, EGFR, and HER2 gene expression after neoadjuvant three-modality treatment in patients with esophageal cancer.
    Schneider S; Uchida K; Brabender J; Baldus SE; Yochim J; Danenberg KD; Salonga D; Chen P; Tsao-Wei D; Groshen S; Hoelscher AH; Schneider PM; Danenberg PV
    J Am Coll Surg; 2005 Mar; 200(3):336-44. PubMed ID: 15737843
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The nuclear transcription factor kappaB/bcl-2 pathway correlates with pathologic complete response to doxorubicin-based neoadjuvant chemotherapy in human breast cancer.
    Buchholz TA; Garg AK; Chakravarti N; Aggarwal BB; Esteva FJ; Kuerer HM; Singletary SE; Hortobagyi GN; Pusztai L; Cristofanilli M; Sahin AA
    Clin Cancer Res; 2005 Dec; 11(23):8398-402. PubMed ID: 16322301
    [TBL] [Abstract][Full Text] [Related]  

  • 29. High orotate phosphoribosyltransferase gene expression predicts complete response to chemoradiotherapy in patients with squamous cell carcinoma of the esophagus.
    Kajiwara T; Nishina T; Hyodo I; Moriwaki T; Endo S; Nasu J; Hori S; Matsuura B; Hiasa Y; Onji M
    Oncology; 2009; 76(5):342-9. PubMed ID: 19307741
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tumor budding in tumor invasive front predicts prognosis and survival of patients with esophageal squamous cell carcinomas receiving neoadjuvant chemotherapy.
    Miyata H; Yoshioka A; Yamasaki M; Nushijima Y; Takiguchi S; Fujiwara Y; Nishida T; Mano M; Mori M; Doki Y
    Cancer; 2009 Jul; 115(14):3324-34. PubMed ID: 19452547
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tumor angiogenesis as a predictive marker for organ preservation in patients with advanced laryngeal carcinoma.
    Teknos TN; Cox C; Barrios MA; Chepeha DB; Bradford CR; Fisher SG; Wolf GT
    Laryngoscope; 2002 May; 112(5):844-51. PubMed ID: 12150616
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Assessment of apoptosis in oesophageal carcinoma preoperatively treated by chemotherapy and radiotherapy.
    Moreira LF; Naomoto Y; Hamada M; Kamikawa Y; Orita K
    Anticancer Res; 1995; 15(2):639-44. PubMed ID: 7539243
    [TBL] [Abstract][Full Text] [Related]  

  • 33. p53 Mutation status predicts pathological response to chemoradiotherapy in locally advanced esophageal cancer.
    Makino T; Yamasaki M; Miyata H; Yoshioka S; Takiguchi S; Fujiwara Y; Nakajima K; Nishida T; Mori M; Doki Y
    Ann Surg Oncol; 2010 Mar; 17(3):804-11. PubMed ID: 19885698
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Preoperative combined modality therapy with paclitaxel, carboplatin, prolonged infusion 5-fluorouracil, and radiation therapy in localized esophageal cancer: preliminary results of a Minnie Pearl Cancer Research Network phase II trial.
    Meluch AA; Hainsworth JD; Gray JR; Thomas M; Whitworth PL; Davis JL; Greco FA
    Cancer J Sci Am; 1999; 5(2):84-91. PubMed ID: 10198730
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Predictive and prognostic markers in a series of patients with head and neck squamous cell invasive carcinoma treated with concurrent chemoradiation therapy.
    Gasparini G; Bevilacqua P; Bonoldi E; Testolin A; Galassi A; Verderio P; Boracchi P; Guglielmi RB; Pezzella F
    Clin Cancer Res; 1995 Nov; 1(11):1375-83. PubMed ID: 9815934
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Neoadjuvant chemotherapy (FAP) for advanced esophageal cancer.
    Shimakawa T; Naritaka Y; Asaka S; Isohata N; Murayama M; Konno S; Yoshimatsu K; Shiozawa S; Katsube T; Ogawa K
    Anticancer Res; 2008; 28(4C):2321-6. PubMed ID: 18751413
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prognostic significance of age in the radical treatment of oesophageal cancer with surgery or chemoradiotherapy: a prospective observational cohort study.
    Davies L; Lewis WG; Arnold DT; Escofet X; Blackshaw G; Gwynne S; Evans M; Roberts SA; Appadurai I; Crosby TD
    Clin Oncol (R Coll Radiol); 2010 Sep; 22(7):578-85. PubMed ID: 20591633
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Impact of circumferential resection margin distance on locoregional recurrence and survival after chemoradiotherapy in esophageal squamous cell carcinoma.
    Chao YK; Yeh CJ; Chang HK; Tseng CK; Chu YY; Hsieh MJ; Wu YC; Liu HP
    Ann Surg Oncol; 2011 Feb; 18(2):529-34. PubMed ID: 20697822
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [A prospective comparison between surgery alone and postoperative chemoradiotherapy for locally advanced esophageal squamous cell carcinoma].
    Cao XF; Lü J; Zhu B; An HY; Wang S; Wu BC; Ji L; Tao L; Wang DD
    Zhonghua Zhong Liu Za Zhi; 2010 Jun; 32(6):452-5. PubMed ID: 20819489
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Neoadjuvant treatment in surgery of esophageal cancer].
    Launois B; Raoul JL; Leprise E; Meunier B
    Bull Acad Natl Med; 2000; 184(8):1703-13; discussion 1714. PubMed ID: 11471389
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.